1️⃣ Madrigal is turning MASH into genotype segmentation
Madrigal licensed Arrowhead’s ARO-PNPLA3 on May 5 for $25M upfront, up to $975M in milestones and royalties, adding a Phase 1 siRNA for MASH patients with the PNPLA3 I148M variant.
💡 Why it matters
Rezdiffra made MASH druggable. This starts slicing the market by genetic risk, which changes trial design, positioning and who gets treated first.
☕ Coffee talk
If MASH now needs a genotype layer, how many broad obesity-adjacent liver pitches still look precise enough?
2️⃣ Vertex just closed the inhaled mRNA CF route
Vertex ended the Phase 1/2 VX-522 study after persistent tolerability issues, and Moderna said the early stop prevents efficacy and full safety assessment of the CFTR mRNA program.
💡 Why it matters
This was one of the cleaner tests of inhaled mRNA for patients who do not benefit from CFTR modulators. Delivery, not target biology, remains the expensive part.
☕ Coffee talk
How many lung mRNA programs still get credit before someone proves the delivery can behave?
3️⃣ Viridian has a second shot at reshaping TED
Viridian’s subcutaneous elegrobart met the primary endpoint in chronic thyroid eye disease: 50% and 54% proptosis responder rates at week 24 for Q4W and Q8W dosing, versus 15% placebo.
💡 Why it matters
TED is moving from single IV incumbent to a route-and-access fight. Viridian now has positive pivotal data in active and chronic disease, with a BLA planned for Q1 2027.
☕ Coffee talk
If the data are enough, does the market choose the best antibody or the easiest treatment day?